Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23924422)

1.

Regulatory T cells in renal cell carcinoma: additional fuel to the bonfire of debate.

Afzali B, Lombardi G.

BJU Int. 2013 Sep;112(5):538-9. doi: 10.1111/bju.12190. No abstract available.

PMID:
23924422
2.

Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma.

Finke JH, Tubbs R, Connelly B, Pontes E, Montie J.

Ann N Y Acad Sci. 1988;532:387-94. No abstract available.

PMID:
2972244
3.

Effects of interleukin-2 treatment on CD1d-restricted natural killer T cells.

Sandberg JK, Moll M.

Clin Cancer Res. 2007 Jul 15;13(14):4311; author reply 4311-2. No abstract available.

4.

The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients.

Schendel DJ, Falk CS, Frankenberger B, Noessner E, Schleypen J, Pohla H.

Urologe A. 2004 Sep;43 Suppl 3:S133-5. No abstract available.

PMID:
15179552
5.

[Activity of natural killer (NK) cells and their stimulation in patients with hypernephroma].

Hofmann R, Lehmer A, Reidel G.

Helv Chir Acta. 1984 Oct;51(3-4):411-5. German. No abstract available.

PMID:
6209242
6.
7.

In vitro activation of lymphocytes by interleukin 2 in patients with renal cell carcinoma.

Ziegelbaum MM, Finke JH, Tubbs R, Montie JE, Pontes JE, Lewis I.

Urology. 1989 Feb;33(2):106-9.

PMID:
2783793
8.

Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma.

Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, Guerriero E, Trotta A, Zanotta S, Pucci L, Longo N, Perdonà S, Pignata S, Castello G, Scala S.

BJU Int. 2013 Sep;112(5):686-96. doi: 10.1111/bju.12068. Epub 2013 Mar 15.

PMID:
23495770
9.

Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes.

Shabtai M, Ye H, Frischer Z, Martin J, Waltzer WC, Malinowski K.

J Urol. 2002 Nov;168(5):2216-9.

PMID:
12394762
10.

Lymphocyte therapy of renal cell carcinoma.

Dillman RO.

Expert Rev Anticancer Ther. 2005 Dec;5(6):1041-51. Review.

PMID:
16336095
11.

[Influence of immunological parameters on the effectiveness of systemic and loco-regional immunotherapy in disseminated renal carcinoma].

Granov AM, Molchanov OE, Karelin MI, Shkol'nik MI, Krotova OA.

Vopr Onkol. 2009;55(5):580-5. Russian.

PMID:
20020653
12.

Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.

Kroeze SG, Daenen LG, Nijkamp MW, Roodhart JM, de Gast GC, Bosch JL, Jans JJ.

J Urol. 2012 Aug;188(2):607-14. doi: 10.1016/j.juro.2012.03.116. Epub 2012 Jun 15.

PMID:
22704448
13.

Kidney cancer: cracking resistance of RCCs against NK-cell-mediated lysis.

Thoma C.

Nat Rev Urol. 2014 Dec;11(12):662. doi: 10.1038/nrurol.2014.300. Epub 2014 Oct 28. No abstract available.

PMID:
25348168
14.

Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma.

Minárik I, Lašťovička J, Budinský V, Kayserová J, Spíšek R, Jarolím L, Fialová A, Babjuk M, Bartůňková J.

Immunol Lett. 2013 May;152(2):144-50. doi: 10.1016/j.imlet.2013.05.010. Epub 2013 May 27.

PMID:
23721909
15.

Killing of Fas ligand-resistant renal carcioma cells by interleukin-2- and BCG-activated effector cells.

Brandau S, Suttmann H, Flad HD, Jocham D, Böhle A.

Cancer Immunol Immunother. 2000 Sep;49(7):369-76.

PMID:
10999463
16.

[Immunological study of anti-cancer effects of human alpha interferon for advanced renal cell carcinoma].

Marumo K, Hayakawa M, Murai M, Tazaki H.

Nihon Hinyokika Gakkai Zasshi. 1985 Jul;76(7):965-73. Japanese. No abstract available.

PMID:
4079199
17.

Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A.

J Immunol. 2005 Feb 1;174(3):1338-47.

18.

[Therapeutic indication of interferons for renal cell carcinoma].

Harano M, Naito S.

Nihon Rinsho. 2006 Feb;64 Suppl 2:647-51. Review. Japanese. No abstract available.

PMID:
16523970
20.

Augmentation of cell-mediated cytotoxicity against renal carcinoma cells by recombinant interleukin 2.

Marumo K, Ueno M, Muraki J, Baba S, Tazaki H.

Urology. 1987 Oct;30(4):327-32.

PMID:
3116737
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk